✦ LIBER ✦

Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

✍ Scribed by Jignesh J. Patel; Margaret A.S. Mendes; Mark Bounthavong; Melissa L.D. Christopher; Daniel Boggie; Anthony P. Morreale

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness sequential modeling o

✍ S. Y. Cohen; D. Bremond-Gignac; G. Quentel; G. Mimoun; T. Citterio; S. Bisot-Loc 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 198 KB

Ranibizumab: A Review of Its Use in the

✍ James E. Frampton 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 752 KB

A Cost-Utility Analysis of Ranibizumab i

✍ de Pouvourville, G.; Lafuma, A.; Moeremans, K.; Nivelle, E.; Umuhire, D.; Gerlie 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Bevacizumab versus ranibizumab in the tr

✍ De Bats, F.; Grange, J.-D.; Cornut, P.-L.; Feldman, A.; Burillon, C.; Denis, P.; 📂 Article 📅 2012 🏛 Masson Editeur 🌐 English ⚖ 267 KB

Cost-Minimization Analysis of Intravitre

✍ Garcia-Layana, A.; Ortega, A.; Ruiz-Moreno, J.M.; Figueroa, M.S.; Farres, J.; Me 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Cost-effectiveness of ranibizumab for th

✍ Aljoscha S. Neubauer; Frank G. Holz; Stefan Sauer; Timo Wasmuth; Christoph Hirne 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 145 KB